Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.01 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Sandisk (SNDK) June 26 weekly calls and puts active, share price down 11.8% into Micron (MU) quarter results
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance